{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:09:34Z","timestamp":1790622574641,"version":"4.1.0"},"reference-count":49,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:00:00Z","timestamp":1762041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2025,11,2]]},"DOI":"10.1080\/17512433.2025.2587174","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T02:33:01Z","timestamp":1762828381000},"page":"837-846","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Impact of gabapentinoids\u2019 reclassification policy and COVID-19 on gabapentinoids\u2019 utilization pattern and their associated mortality in Scotland and Northern Ireland: a segmental regression analysis"],"prefix":"10.1080","volume":"18","author":[{"given":"Abdullah","family":"Alrahmani","sequence":"first","affiliation":[{"name":"University of Strathclyde","place":["Glasgow, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabast","family":"Azeez","sequence":"additional","affiliation":[{"name":"University of Strathclyde","place":["Glasgow, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Baker","sequence":"additional","affiliation":[{"name":"University of Technology and Applied Sciences","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanj","family":"Kurdi","sequence":"additional","affiliation":[{"name":"University of Strathclyde","place":["Glasgow, UK"]},{"name":"Al-Kitab University","place":["Kirkuk, Iraq"]},{"name":"Sefako Makgatho Health Sciences University","place":["Pretoria, South Africa"]},{"name":"Hawler Medical University","place":["Erbil, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1178221818801311"},{"key":"e_1_3_6_3_1","unstructured":"BNF. NICE. [cited 2925 May 7]. Available from: https:\/\/bnf.nice.org.uk"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002369"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0700-x"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000321079"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.732345"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2024.1513597"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100579"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.02.032"},{"issue":"1","key":"e_1_3_6_11_1","first-page":"CD007076","article-title":"Pregabalin for neuropathic pain in adults","volume":"2019","author":"Derry S","year":"2019","unstructured":"Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;2019(1):CD007076.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2021.107143"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0164-4"},{"key":"e_1_3_6_14_1","unstructured":"Reclassification of pregabalin and gabapentin to schedule 3 drugs from 1 April 2019. GOV.UK; [cited 2025 May 11]. Available from: https:\/\/www.gov.uk\/government\/news\/reclassification-of-pregabalin-and-gabapentin-to-schedule-3-drugs-from-1-april-2019"},{"key":"e_1_3_6_15_1","unstructured":"3.6 Controlled Drugs. [cited 2025 May 7]. Available from: https:\/\/www.rpharms.com\/mep\/3-underpinning-knowledge-legislation-and-professional-issues\/36-controlled-drugs#gsc.tab=0"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.15190\/d.2021.20"},{"issue":"9","key":"e_1_3_6_17_1","first-page":"95","article-title":"COVID-19 pandemic impact on mental health of vulnerable populations","volume":"91","author":"Amerio A","year":"2020","unstructured":"Amerio A, Aguglia A, Odone A, et al. COVID-19 pandemic impact on mental health of vulnerable populations. Acta Bio Medica : Atenei Parmensis. 2020;91(9\u2013S):95.","journal-title":"Acta Bio Medica : Atenei Parmensis"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1467144"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276867"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5628"},{"key":"e_1_3_6_22_1","unstructured":"Publications - Public Health Scotland. [cited 2025 May 24]. Available from: https:\/\/www.publichealthscotland.scot\/publications\/?ic=phs_publication_type-statistical-report&q=&fq=phs_publication_type%3AStatistical+report%23&sort=pdesc"},{"key":"e_1_3_6_23_1","unstructured":"GP Datasets. [cited 2025 May 24]. Available from: https:\/\/gpdatasets.hscni.net\/"},{"key":"e_1_3_6_24_1","unstructured":"2 years of COVID-19 on GOV.UK \u2013 Government Digital Service. [cited 2025 May 26]. Available from: https:\/\/gds.blog.gov.uk\/2022\/07\/25\/2-years-of-covid-19-on-gov-uk\/"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw098"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaa118"},{"key":"e_1_3_6_27_1","unstructured":"Introduction to drug utilization research [Internet]. World Health Organisation; 2003 [cited 2025 May 11]. Available from: https:\/\/iris.who.int\/handle\/10665\/42627"},{"key":"e_1_3_6_28_1","unstructured":"Population estimates time series data - National Records of Scotland (NRS). [cited 2025 May 25]. Available from: https:\/\/www.nrscotland.gov.uk\/publications\/population-estimates-time-series-data\/"},{"key":"e_1_3_6_29_1","unstructured":"Population | Northern Ireland Statistics and Research Agency [Internet]. [cited 2025 May 25]. Available from: https:\/\/www.nisra.gov.uk\/statistics\/people-and-communities\/population"},{"key":"e_1_3_6_30_1","unstructured":"ATCDDD - ATC\/DDD Index. [cited 2025 May 13]. Available from: https:\/\/atcddd.fhi.no\/atc_ddd_index\/?code=N02BF&showdescription=no"},{"key":"e_1_3_6_31_1","unstructured":"Drug-related deaths in Scotland in 2023 - National Records of Scotland (NRS). [cited 2025 Jun 24]. Available from: https:\/\/www.nrscotland.gov.uk\/publications\/drug-related-deaths-in-scotland-in-2023\/"},{"key":"e_1_3_6_32_1","unstructured":"Drug-related deaths | Northern Ireland Statistics and Research Agency [Internet]. [cited 2025 Jun 24]. Available from: https:\/\/www.nisra.gov.uk\/statistics\/cause-death\/drug-related-deaths"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2025.2473613"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2024.2368816"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2024.2363485"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2093715"},{"key":"e_1_3_6_38_1","unstructured":"Home. [cited 2025 Jun 22]. Available from: https:\/\/www.sign.ac.uk\/"},{"key":"e_1_3_6_39_1","unstructured":"Formulary ni formulary [Internet]. [cited 2025 Jun 22]. Available from: https:\/\/niformulary.hscni.net\/formulary\/"},{"key":"e_1_3_6_40_1","unstructured":"Issue 7- July 2021 | NI Formulary [Internet]. [cited 2025 Jun 24]. Available from: https:\/\/niformulary.hscni.net\/wpfd_file\/issue-7-july-2021\/"},{"key":"e_1_3_6_41_1","volume-title":"Overview neuropathic pain in adults: pharmacological management in non-specialist settings guidance","author":"National Institute of Health and care Excellence","year":"2020","unstructured":"National Institute of Health and care Excellence. Overview neuropathic pain in adults: pharmacological management in non-specialist settings guidance. NICE; 2020. https:\/\/www.nice.org.uk\/guidance\/cg173"},{"key":"e_1_3_6_42_1","unstructured":"Cps members area | Drug tariff. [cited 2025 Oct 19]. Available from: https:\/\/members.cps.scot\/drug-tariff\/?SearchText=Pregabalin"},{"key":"e_1_3_6_43_1","unstructured":"HSCNI Business Services Organisation. Dentist & nurse prescriber formularies. 2025 [cited 2025 Oct 19]. Available from: https:\/\/bso.hscni.net\/wp-content\/uploads\/2025\/05\/DT_Part_9-Dentists-and-Nurses-Prescriber-Formularies_2506.pdf"},{"key":"e_1_3_6_44_1","unstructured":"Recent changes in controlled drug legislation for tramadol lisdexamfetamine zopiclone and zalepon \u2013 NECS medicines optimisation. [cited 2025 Jun 25]. Available from: https:\/\/medicines.necsu.nhs.uk\/recent-changes-in-controlled-drug-legislation-for-tramadol-lisdexamfetamine-zopiclone-and-zapelon\/"},{"key":"e_1_3_6_45_1","unstructured":"Evaluation of opioid-related deaths associated with opioid utilisation and the impacts of tramadol classification as a Schedule III controlled drug in the United Kingdom - Nottingham ePrints. [cited 2025 Jun 25]. Available from: https:\/\/eprints.nottingham.ac.uk\/56471\/?utm_source=chatgpt.com"},{"key":"e_1_3_6_46_1","unstructured":"PCA(P)(2021)01 - NHS medicines delivery service | Community Pharmacy Scotland. [cited 2025 Sep 3]. Available from: https:\/\/www.cps.scot\/latest-news\/pcap202301-nhs-medicines-delivery-service\/"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13854"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104660"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101424"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02158-7"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2025.2587174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T07:19:33Z","timestamp":1766733573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2025.2587174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,2]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,2]]}},"alternative-id":["10.1080\/17512433.2025.2587174"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2025.2587174","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}